Drug intelligence / Profile preview

BIO018

Development stage: Preclinical
Lead developer: Biom Pharmaceutical
Modality: Small Molecules

Overview

BIO018 is a small molecule therapeutic candidate being developed by Biom Therapeutics for the treatment of neurodegenerative and neuroinflammatory disorders. The drug is designed to modulate 5-hydroxytryptamine receptor 2 (5-HT2R) and microglial complement receptor 2 (CR2), targeting neuropathological processes associated with neuroinflammation. BIO018 is currently in the research and preclinical stages of development for several indications, including CLN 6-7 deficiency disorders (forms of Batten disease), Alzheimer's disease, and HIV-associated dementia.

Targets

5-HT2 (5-HT2 receptor family)CR2 (Complement receptor type 2)

Beyond the preview

Go deeper on BIO018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO018.

Explore the full profile